Multicenter Phase II study of erlotinib for advanced or recurrent non-small cell lung cancer with Epidermal Growth factor Receptor (EGFR) mutation (TORG0911)
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000003313
- Lead Sponsor
- Thoracic Oncology Research Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Not provided
1)previous radiotherapy to primary lung cancer 2)superior vena caval syndrome 3)severe drug allergy 4)large peritoneal or pericardial effusion 5)active infection 6)continuous watery diarrhea 7)intestinal paralysis or ileus 8)interstitial pneumonia or lung fibrosis evident on CT 9)symptomatic ophthalmologic disease 10)current or previous (within the last 1 year) history of GI perforation 11)serious non-healing ulcer 12)Symptomatic or steroid-requiring brain metastases 13),14)active concomitant malignancy 15)uncontrolled diabetes 16)severe cardiac disease 17)severe psychological disease 18)pregnant or lactating women or those who declined contraception 19)those judged to be not suitable by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method